GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
E

EPS Bio Technology 4183.TWO · TWD

Health Care · Taipei Exchange · 🇹🇼 Taiwan

Compare

14.40

—

Close of 9 Nov 2026, in TWD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About EPS Bio Technology

Its shares trade on Taipei Exchange under the ticker 4183.TWO. It has been listed since 13 November 2012. In the fiscal year to 31 December 2025, it reported revenue of TWD 499.7m and a net loss of TWD 7.9m. At that date it held total assets of TWD 533.2m and shareholders' equity of TWD 281.1m.

EPS Bio Technology Corp. engages in the development and manufacture of blood glucose monitoring systems and the development and sales of various medical and related medical equipment. The company is headquartered in Baoshan, Hsinchu. The company went IPO on 2012-11-13. The firm's main products include blood glucose testers, blood glucose test strips and electric breast pumps. The firm distributes its products mainly to overseas markets, such as Europe, North America and the rest areas of Asia.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Health Care Equipment & Supplies
Listed since
13 Nov 2012
Employees
123

Leadership

Pay as last reported

  • Mr. Feng-Lin KuoChairman of the Board, since 2011
  • Mr. Lien-Fu LiuVice Chairman of the Board, since 2015
  • Mr. Cheng-Hui ChoGeneral Manager, Corporate Governance Officer
  • Mr. Boxiong GuoDeputy General Manager, Head of Finance, Director, since 2015
  • Zhiheng LinDeputy General Manager-Research & Development
  • Mr. Qingnian LuoDeputy General Manager
  • Zhitai HuangHead of Accounting
  • Mr. Chuijin LinDirector
  • Mr. Yifan YouDirector
  • Mr. Hongzhe ZhangDirector
  • Ms. Hsin-Yu ChungIndependent Director
  • Mr. Yushan LuIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • EPS Bio Technology Corp. develops blood glucose monitoring systems in the Health Care sector.
  • The company manufactures blood glucose testers and test strips for global markets.
  • Overseas distribution to Europe, North America, and Asia boosts market reach.

Weaknesses

  • Limited domestic market presence in Taiwan despite headquarters location.
  • Reliance on overseas markets for product distribution channels.
  • Employees count of 123 may limit scalability in production capacity.

Opportunities

  • Growing demand for blood glucose monitoring systems in aging populations.
  • Expansion into new medical equipment markets within Health Care sector.
  • Increasing global health awareness drives sales of medical devices.

Threats

  • Competition from established medical device manufacturers in Europe.
  • Economic fluctuations in North American and Asian markets affect sales.
  • Regulatory changes in overseas markets could disrupt distribution.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.